Drugs / MT-501
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06762457 | Dec 2024 → May 2025 | — | Mirador Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07113522 | Jun 2025 → Apr 2027 expected | Crohn disease, ulcerative colitis | Mirador Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06762457 ↗ |
| Route | Oral | “single and repeat oral doses of MT-501” NCT06762457 ↗ |